NYSE:BMY 24 December 2025

Amazon Shares Slip After $17.5 Billion AI Loan Draws Focus to AMZN Cash Flow

Amazon takes number one spot on 2026 Fortune 500; regional shifts seen

Amazon has taken the No. 1 spot on the 2026 Fortune 500, Fortune said, unseating Walmart after 13 years at the top. The change put Amazon ahead for the first time in more than a decade and drove shifts in regional tallies for Pennsylvania, New Jersey and New England. Fortune’s 72nd annual list put the collective revenue at $21.0 trillion, with profits at $2.1 trillion and a workforce of 30.5 million worldwide.

15 June 2026

NASDAQ:AMZN·NASDAQ:ERIE·NYSE:BMY·NYSE:BSX·NYSE:CVS·NYSE:JNJ·NYSE:MRK·NYSE:PBF·NYSE:PRU·NYSE:TJX·NYSE:WMT·Stock Market

Replimune jumps 85% after FDA opens up third dose for skin cancer therapy

Replimune Group shares rallied Friday afternoon. The company said it reached a deal with the U.S. Food and Drug Administration to resubmit RP1, its experimental advanced melanoma drug. Shares jumped $3.96, or roughly 85%, to $8.64 after hitting $9.05. The SPDR S&P Biotech ETF added about 0.8%.

29 May 2026

NASDAQ:RPLM·NYSE:BMY·Stock Market

Johnson & Johnson Moves Tecvayli Earlier in Europe After FDA Myeloma Nod

Johnson & Johnson on Tuesday said it’s filed with the European Medicines Agency to expand Tecvayli’s EU label, aiming to allow the therapy as a single agent for adults with relapsed or refractory multiple myeloma who’ve already had at least one prior treatment. That would move the drug up in the treatment sequence for the blood cancer, where, according to the company, patients still encounter some of the toughest care gaps.

10 March 2026

NYSE:BMY·NYSE:JNJ·NYSE:PFE·Stock Market

Bristol Myers Squibb stock rises on 2026 guidance as Eliquis price cut comes into view

Bristol Myers Squibb shares climbed 1.7% to $58.58 by midday Thursday, having peaked earlier at $60.54. This came as the S&P 500 slipped around 0.7%, with health-care stocks also drifting lower.

5 February 2026

NYSE:BMY·Pharmaceuticals·Stock Market

Microsoft stock dips after-hours as Bristol Myers AI lung-cancer deal lands and tariff jitters shake tech

Shares of Microsoft Corp dipped 1.1% to $454.52 in after-hours trading Tuesday, moving between $449.06 and $456.76 during the session. The software giant’s market cap stands near $3.85 trillion.

20 January 2026

Artificial Intelligence·NASDAQ:MSFT·NYSE:BMY·Stock Market

Nvidia stock slides as Trump tariff threats hit AI stocks; Microsoft, Broadcom fall

Nvidia shares slipped roughly 3.4% to $179.83 in early Tuesday trading, weighing down a cluster of AI stocks that remain vulnerable to changes in risk appetite.

20 January 2026

Artificial Intelligence·NASDAQ:AMD·NASDAQ:AVGO·NASDAQ:GOOGL·NASDAQ:INTC·NASDAQ:MSFT·NASDAQ:NFLX·NASDAQ:NVDA·NASDAQ:PLTR·NASDAQ:SMCI·NYSE:BMY·Stock Market·US Economy

AbbVie stock slides after Epkinly trial misses survival goal — what ABBV investors watch next

AbbVie’s stock dropped on Friday after partner Genmab announced that a late-stage trial of epcoritamab failed to meet its primary endpoint of improving overall survival in blood cancer patients. AbbVie closed at $214.35, down 1.1%. Genmab’s U.S.-listed shares tumbled over 7%. The companies said they still expect data from two other late-stage epcoritamab trials in 2026, including studies combining the drug with standard chemotherapy and Bristol Myers Squibb’s Revlimid.

18 January 2026

NASDAQ:GMAB·NYSE:ABBV·NYSE:BMY·Pharmaceuticals·Stock Market

Tempus AI stock pops 12% premarket after $1.1 billion contracts update — what traders watch next

Tempus AI shares climbed roughly 12%, reaching $74.34 in Monday's premarket session.

12 January 2026

NYSE:AZN·NYSE:BMY·NYSE:GSK·NYSE:MRK·NYSE:NVS·NYSE:PFE·Stock Market

Bristol Myers Squibb (BMY) stock jumps on UBS upgrade as investors look to January catalysts

Bristol Myers Squibb shares rose 4.2% to $56.72 on Wednesday after UBS upgraded the drugmaker to buy and lifted its price target to $65 from $46. TipRanks

8 January 2026

NYSE:BMY·Stock Market

Bristol-Myers Squibb (BMY) stock fell Friday — here’s what investors are watching next

Bristol-Myers Squibb shares ended down 0.9% at $53.46 on Friday, after the company confirmed it will present at J.P. Morgan’s annual healthcare conference on Jan. 12. JPMorgan Chase

3 January 2026

NYSE:BMY·Pharmaceuticals·Stock Market

Cytokinetics (CYTK) stock ends 2025 higher as Myqorzo launch nears — what’s next

Cytokinetics, Incorporated shares rose $2.17, or 3.5%, to $63.54 in the last trading session of 2025, after swinging between $60.93 and $64.43 on volume of about 1.85 million shares. U.S. markets were shut on Thursday for the New Year’s Day holiday. Yahoo Finance

1 January 2026

Biotechnology·NASDAQ:CYTK·NYSE:BMY·Pharmaceuticals·Stock Market

Bristol-Myers Squibb stock edges higher as Wall Street drifts into year-end — what’s next for BMY

Bristol-Myers Squibb Co. shares closed up 0.18% at $54.21 on Tuesday, after trading between $53.92 and $54.35. The stock has ranged from $42.52 to $63.33 over the past 52 weeks. Bristol Myers Squibb Investors

31 December 2025

NYSE:BMY·Pharmaceutical Industry·Stock Market

Bristol Myers Squibb stock slips today as year-end trading thins and dividend date nears

Bristol Myers Squibb shares fell on Monday, with the drugmaker lagging a slightly weaker U.S. stock market in holiday-thinned trading. The stock was down 0.7% at $54.27 in afternoon trade.

29 December 2025

Dividends·NYSE:BMY·Pharmaceuticals·Stock Market

Bristol Myers stock drifts near $55 as year-end trading thins and Fed minutes loom

Bristol Myers Squibb shares ended Friday slightly lower at $54.64, as the U.S. market headed into the year’s final trading days with few fresh company-specific catalysts. Bristol Myers Squibb

29 December 2025

NYSE:BMY·Stock Market

Bristol Myers Squibb (BMY) Stock: Weekend News, Analyst Targets, Dividend Update, and What to Watch Before Monday’s Open

Bristol Myers Squibb Company enters the final trading stretch of 2025 with investors balancing a defensive “big pharma” profile and above-market income appeal against policy headlines and the long-running question hanging over the name: how quickly can new launches and pipeline catalysts offset upcoming loss-of-exclusivity pressure in key franchises?

28 December 2025

Financial Insights·NYSE:BMY

Bristol-Myers Squibb (BMY) Stock: What Investors Should Watch Before Monday’s Open as Dividend Date, Earnings, and 2026 Catalysts Come Into Focus

Bristol-Myers Squibb Company heads into the final week of 2025 with U.S. markets shut for the weekend and investor attention shifting to what could matter most when trading resumes Monday: year-end positioning, the company’s next dividend timeline, the next earnings checkpoint, and a set of 2026 regulatory and pipeline milestones that could influence sentiment around the stock.

27 December 2025

Dividends·Earnings Reports·NYSE:BMY·Stock Market

Bristol-Myers Squibb (BMY) Stock: Weekend Market Close, Fresh Institutional Filings, and What to Watch Before Monday’s Open

Bristol-Myers Squibb Company stock is heading into the weekend with U.S. equity markets closed, leaving investors to digest the latest batch of institutional ownership updates and re-check near-term catalysts that could matter when trading resumes Monday. The pharmaceutical giant finished the most recent regular session essentially flat, while broader benchmarks also showed little movement—typical of late-December, liquidity-thinner trading. Bristol Myers Squibb Investors

27 December 2025

NYSE:BMY·Stock Market

Bristol-Myers Squibb (BMY) Stock News, Forecasts and Outlook as of Dec. 25, 2025: Breyanzi FDA Win, Eliquis Medicaid Deal, and 2026 Catalysts

With U.S. markets effectively pausing for the holiday, the most recent available NYSE quote showed BMY around $54.71, after trading between roughly $54.20 and $54.75 intraday. Bristol Myers Squibb Investors

25 December 2025

Financial Forecasts·NYSE:BMY·Pharmaceutical Industry·Stock Market

Bristol-Myers Squibb (BMY) Stock After Hours on Dec. 24, 2025: Key News, Forecasts, and What to Watch Before the Next Market Open

Bristol-Myers Squibb Company ended the Christmas Eve session with a modest gain—and then stayed largely quiet in after-hours trading as U.S. markets wrapped an early close and investors looked ahead to the next full session on Friday, Dec. 26. New York Stock Exchange

25 December 2025

NYSE:BMY·Pharmaceutical Industry·Stock Market

Bristol-Myers Squibb (BMY) Stock After Hours on Dec. 23, 2025: Key News, Analyst Forecasts, and What to Watch Before the Dec. 24 Market Open

Bristol-Myers Squibb Company ended Tuesday, December 23, 2025, slightly lower in regular trading, then steadied after the closing bell as investors digested a fresh legal headline tied to U.S. drug pricing—plus a growing list of end‑of‑year catalysts that could shape sentiment into 2026.

24 December 2025

NYSE:BMY·Stock Market

NYSE:BMY 24 December 2025 - 15 June 2026